Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

3.535 +0.185 (+5.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 360,520
Open 3.310
Bid (Size) 3.510 (1)
Ask (Size) 3.580 (1)
Prev. Close 3.350
Today's Range 3.310 - 3.580
52wk Range 2.120 - 19.95
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
From Mind Medicine (MindMed) Inc.
Via Business Wire

Performance

YTD
+41.97%
+41.97%
1 Month
-7.70%
-7.70%
3 Month
-3.68%
-3.68%
6 Month
+30.93%
+30.93%
1 Year
-73.95%
-73.95%

More News

Read More
MindMed Calls FDA Experts To Validate LSD Drug Development Strategy
Via Benzinga
MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
From Mind Medicine (MindMed) Inc.
Via Business Wire
Mind Medicine: Q1 Earnings Insights
Via Benzinga
MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
From MindMed
Via Business Wire
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Via Benzinga
MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected
Via Benzinga
MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
From MindMed
Via Business Wire
Earnings Outlook For Mind Medicine
Via Benzinga
FCM Holdings Accuse MindMed Braintrust Of 'Pursuing Misguided Clinical Path for MM-120'
Via Benzinga
FCM Director Nominees Will Put MindMed Drug Development Process Back on Track
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
Via Benzinga
MindMed Reports Q1 2023 Financial Results, Business Highlights, Upcoming Elections
Via Benzinga
FCM Releases Letter to Fellow MindMed Shareholders Highlighting Board and Management’s Track Record of Shareholder Value Destruction
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
MindMed Reports First Quarter 2023 Financial Results and Business Highlights
From MindMed
Via Business Wire
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
From MindMed
Via Business Wire
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Via Benzinga
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
From Mind Medicine (MindMed) Inc.
Via Business Wire
3 High-Growth Penny Stocks to Consider Buying in April 2023
Via InvestorPlace
April Psychedelic Drug Stocks Recap: The Ups And Downs
Via Talk Markets
MindMed CEO On Latest Positive Topline Phase 2 Data And Freedom Capital Management
Via Benzinga
MindMed to Participate in May Investor Conferences
From MindMed
Via Business Wire
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Via Benzinga
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.